Literature DB >> 10720549

Lack of immunity in university students before an outbreak of serogroup C meningococcal infection.

G R Jones1, J N Williams, M Christodoulides, K Jolley, J E Heckels.   

Abstract

Immunity to meningococci was determined in infected and uninfected students before and during an outbreak of serogroup C meningococcal infection at a university in the United Kingdom. No immunity against the outbreak strain was detected in serum taken from infected students prior to the outbreak or at the time of admission; bactericidal activity developed during convalescence. Carriage of all strains of serogroup C meningococci in asymptomatic students was low (0.9%), and no carriage of the outbreak strain could be detected. Immunity in the at-risk student population before the outbreak was low: 90% of students had no significant bactericidal activity against the outbreak strain. A low prevalence of carriage of the outbreak strain, together with a low prevalence of protective immunity within the student population, was associated with a high incidence of invasive disease in those who acquired the outbreak strain.

Entities:  

Mesh:

Year:  2000        PMID: 10720549     DOI: 10.1086/315352

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

2.  Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.

Authors:  P Richmond; R Borrow; J Findlow; S Martin; C Thornton; K Cartwright; E Miller
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides.

Authors:  Sarika Agarwal; Shreekant Vasudhev; Rosane B DeOliveira; Sanjay Ram
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

Review 7.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

8.  Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis.

Authors:  J Claire Wright; Jeannette N Williams; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

9.  Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America.

Authors:  Andrew J Pollard; Jan Ochnio; Margaret Ho; Martin Callaghan; Mark Bigham; Simon Dobsong
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

Review 10.  Meningococcal disease and the complement system.

Authors:  Lisa A Lewis; Sanjay Ram
Journal:  Virulence       Date:  2013-10-08       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.